Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BA | Common Stock | Award | $0 | +3.33K | +31.93% | $0.00 | 13.8K | Feb 16, 2022 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BA | Stock Option (Right to Buy) | Award | $0 | +8.73K | $0.00 | 8.73K | Feb 16, 2022 | Common Stock | 8.73K | $260.98 | Direct | F2, F3 |
Id | Content |
---|---|
F1 | Represents restricted stock units that will vest and settle in shares of the Company's common stock on a one-for-one basis on February 17, 2025. |
F2 | The exercise price is equal to 120% of the average of the high and the low trading prices on the date of the grant (the "Grant Date FMV"). The exercise price will be reduced to 110% of the Grant Date FMV if the issuer's total shareholder return ("TSR") over the three-year vesting period exceeds the median TSR for the peer group of companies listed in the award agreement. |
F3 | The option becomes vested and exercisable in full on February 16, 2025, which is the third anniversary of the date of grant. |
dandridgepoa.txt